BeiGene reveals plans to set up new R&D facility in New Jersey

BeiGene- a Chinese biotechnology company that focuses on developing and commercializing advanced cancer medicines across the globe, has announced its plans to develop a new campus for research and development and manufacturing at the Princeton West innovation Centre in Hopewell, New Jersey.

Notably, the entity has inked a purchase agreement to acquire a nearly 42-acre site with more than one million- sq. feet of developed real estate to build a state-of-the-art unit which is slated to encompass commercial-stage biologic pharmaceutical production, clinical R&D, and set up the BeiGene Center for Pharmacovigilance Innovation.

According to Michael Garvey, Global Head of Technical Operations, BeiGene “the company is expected to close the purchase of site in the third quarter of 2021, with the initial construction expected to be completed in 2023.”  

Along with producing a wide array of medicines and supporting the company’s growth requirements, the facility will eventually be used to produce small-molecule drugs as well.

By opening a new production factory, the biotech giant aims at positioning itself for external collaboration along with developing a talent hub. The firm also aims at advancing the next-gen of patient safety monitoring by partnering and advancing its own efforts to digitalize pharmacovigilance.

It is worth mentioning that the proposed manufacturing site will help expand BeiGene’s global supply chain that is presently restricted to China. The firm operates a small-molecule facility in Suzhou along with a biologics unit in Guangzhou.    

In addition to above, the company has enlisted German pharma company- Boehringer Ingelheim to develop the Novartis-partnered cancer medicine tislelizumab at its factory in Shanghai.   

Post gaining clinical and commercial wins in the last few years, BeiGene has emerged as a leading name in the wide biopharma sector. In May’21, the company had doubled its product sales within the first quarter to USD 106 million.

Source Credit: https://www.fiercepharma.com/marketing/beigene-lays-plans-for-flagship-biologics-plant-and-r-d-center-nj